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Background: Complex metabolic changes cause obesity, making weight loss difficult. For this reason, understanding
metabolism is important, and considering the shortcomings of conventional treatment options for obesity,
acupuncture is a possible option. However, evidence supporting its efficacy on metabolic parameters in obese
patients is lacking. The aim of this study is to investigate the effects of acupuncture on serum metabolic
parameters in premenopausal obese women.
Methods/design: This ongoing study is a randomized, patient-assessor blind, two-arm parallel non-penetrating
sham-controlled clinical trial. Eligible participants, premenopausal adult women (19 years of age or older) with a
clinical diagnosis of obesity (body mass index of 25 kg/m2 or more) blinded to the treatment received, will be
randomly allocated blindly into the real acupuncture treatment group (manual acupuncture plus electroacupuncture,
n = 60) or the sham acupuncture control group (sham acupuncture plus placebo acupuncture without electrical
stimulation, n = 60) and receive treatment two times a week for a total of 12 sessions over 6 weeks. The primary
outcome measure is the serum cholesterol and triglyceride (TG) levels at baseline and endpoint. The secondary
outcomes are body weight, body fat mass, muscle mass, waist and hip circumference, other serum metabolic
profiles, International Physical Activity Questionnaire (IPAQ), Social Readjustment Rating Scale (SRRS), Stress Response
Inventory (SRI), Fatigue Severity Scale (FSS), the Korean version of the Beck Depression Inventory (BDI), and urine
metabolites. Adverse events will be assessed at every visit.
Discussion: The results of this trial (which will be available in 2015) will provide important clinical evidence for
the effect of acupuncture on serum metabolites and demonstrate how acupuncture can be helpful for the
treatment of obesity.
Trial registration: Trial registration registered via US National Institutes of Health Clinical Trials registry
(ClinicalTrials.gov) on 11 November 2014, identifier: NCT02066090.
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Obesity is a major health problem associated with
morbidity (for example, type 2 diabetes mellitus, certain
cancers, and cardiovascular and musculoskeletal diseases)
and premature death [1–4]. Treatment options include
dietary and lifestyle changes, drug interventions, and
bariatric surgery [5]. The UK National Institute for Health
and Clinical Excellence (NICE) advises that lifestyle
changes, including behavioral approaches, should form
the mainstay of obesity management [6]. However, many
studies of dietary and behavioral treatments showed that
maintaining weight loss is difficult when obesity is associ-
ated with various metabolic changes [7] and caused by
complex interactions between environment, genetic pre-
disposition, and personal behavior [8]. Recently, investiga-
tors have applied comprehensive metabolomic profiling to
gain a better understanding of biochemical, endocrine,
inflammatory marker, and physiological differences be-
tween obese and lean human subjects [9, 10].
Given the shortcomings of conventional treatment
options and the importance of understanding metabol-
ism in obesity, acupuncture is a possible treatment
option for obese patients. Three systematic reviews of
randomized controlled trials have shown the benefits of
acupuncture in patients with obesity [11–13]. The
results were promising, but many of the trial compo-
nents were of poor quality. Several studies showed that
acupuncture treatment may specifically aid in weight loss
and reduce obesity by stimulating alpha-melanocyte-
stimulating hormone expression and release [14], enhan-
cing the expression of peroxisome proliferator-activated
receptor gamma mRNA in adipose tissues [15], reducing
blood lipids and fasting blood glucose levels [16], and
upregulating obestatin expression in the hypothalamus
[17]. These results suggested possible mechanisms of
acupuncture for obesity but were inconclusive because
they involved experiments using animal models. A few
clinical trials have examined the effect of acupuncture on
metabolic parameters in obese patients [18].
In this paper, we propose a randomized, patient-assessor
blind, sham-controlled study of patients with obesity, with
a predetermined sample size and appropriate follow-up,
which will help to investigate the efficacy of acupuncture
on obesity from the perspective of metabolomics and
therefore provide a better understanding of the physio-
logical therapeutic mechanism of acupuncture on obesity.
Methods/design
Study design
This study is a two-arm parallel, patient-assessor blinded,
non-penetrating sham-controlled randomized clinical
trial. The trial will be performed in the Korean Medicine
Hospital of Kyung Hee University at Gangdong in Korea
in accordance with the Declaration of Helsinki and theGuidelines for Good Clinical Practice. This protocol was
registered with the US National Institutes of Health Clin-
ical Trials registry. Eligible participants will be randomly
allocated into one of two groups (the real acupuncture
treatment group or the sham acupuncture control group)
in a 1:1 allocation ratio, blinded to the group allocation,
and will receive treatment for 6 weeks (Fig. 1). The
outcome assessment and the statistical analysis will be
performed by professionals blinded to the assignment of
participants to either the real or sham acupuncture.Participants
Inclusion criteria
A total of 120 patients will be recruited through adver-
tisements posted in local newspapers, in the hospital’s
monthly magazine, on a website, and on bulletin boards. If
patients are interested in participating, they will be asked
to answer questions to determine eligibility. The eligibility
criteria for the study include adult women (19 years of age
or older) in premenopausal state with regular menstru-
ation, clinical diagnosis of obesity (body mass index of 25
kg/m2 or more), and signed written informed consent. To
avoid the effect of menopause on obesity and serum meta-
bolic parameters [19], we decided to include only premen-
opausal women.Exclusion criteria
Participants will be excluded if they are experiencing or
have a history of the following: previous or current
endocrine disease such as hypothyroidism or Cushing’s
syndrome, heart disease, lung disease, diabetes, malig-
nant tumor, cholelithiasis, severe kidney impairment,
severe liver impairment, anorexia nervosa or hyperor-
exia; history of taking medicines which might affect
body weight and the concentration of serum metabolic
parameters such as anorectic, laxative, oral steroid,
thyroid hormone, amphetamine, cyproheptadine, and
phenothiazine medicines, or medicines affecting absorp-
tion, metabolism, and excretion during the last 3 months;
history of taking beta blockers or diuretics for the treat-
ment of hypertension during the last 3 months; surgical
treatment for obesity; currently pregnant or breast-
feeding or planning to become pregnant; history of
taking other experimental medicines during the last 1
month; weight loss of 10 % or more of previous body
weight during the last 6 months; stopped smoking
during the last 3 months or have irregular smoking
habits; pacemaker; currently receiving any treatment
for obesity or other inappropriate reasons for inclusion
in this trial, including unwillingness to comply with this
study protocol or inability to complete the study-
related questionnaires by themselves or with assistance,
as assessed by researchers.
Fig. 1 The study flowchart
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Study participants who meet the eligibility criteria will
be randomly assigned to two groups (the real acupunc-
ture treatment group or the sham acupuncture control
group) in a 1:1 ratio at the second visit after signing
written informed consent. Randomization will be con-
ducted using a computer-generated random allocation
sequence by a statistician with no clinical involvement in
this trial, and the random code will be kept by a clinician
who will not contact patients. Blocked randomization will
be employed to ensure balance within the two groups.
Subject details will be recorded, and a treatment arm
and randomization number will be allocated to the
subject. Randomization code will be released after the
participants are recruited for the trial, and all baseline
measures are taken to ensure allocation concealment.
The practitioners will be aware of the allocation arm,
while the subjects, outcome assessors, and statistician
performing the data analysis will be blinded to the
treatment allocation [20]. The blinding credibility of the
real and sham acupuncture treatments will be evaluated
at baseline and at the end of the 6-week treatment [21].
Intervention
Both real and sham acupuncture groups will receive a
total of 10–12 acupuncture sessions. At the time of the
first acupuncture session, all participants will be given a“dietary and exercise manual for obese patients” from
the obesity clinic of the Korean Medicine Hospital of
Kyung Hee University at Gangdong.Real acupuncture treatment group
The real acupuncture group will receive manual acupunc-
ture plus electroacupuncture treatment at the same time
twice a week for 6 weeks; these are common approaches
used by Korean medicine doctors (KMDs) in South Korea
today. The predefined acupuncture points were carefully
selected by a process of consensus with participating
KMDs who all specialize in obesity treatment on the basis
of a literature review regarding acupuncture for obesity.
The 14 acupuncture points used were the following: bilat-
eral Hegu (LI4), Quchi (LI11), Sanyinjiao (SP6), Zusanli
(ST36), middle Qihai (CV6), and Zhongwan (CV12) for
manual acupuncture and bilateral Tianshu (ST25) and
Shuidao (ST28) for electroacupuncture.
Manual acupuncture treatment will be administered
using disposable sterile stainless steel needles (40 mm ×
0.25 mm; Dong-bang Acupuncture Inc., Seoul, Korea)
to the 10 acupuncture points mentioned above with the
aid of the tube of a sham acupuncture needle device.
The needles will be inserted perpendicularly to a depth
of 5–20 mm, with the patient lying down and blind-
folded after skin sterilization, followed by bidirectional
Kim et al. Trials  (2015) 16:327 Page 4 of 8rotation to induce deqi sensation. The needles will then
be left in place for 30 minutes.
At the same time, electroacupuncture treatment will
be administered using disposable sterile stainless steel
needles (90 mm × 0.25 mm; Dong-bang Acupuncture
Inc.) and a LipoDR low-frequency electroacupuncture
device (Dow Meditec Corp., Seoul, Korea) to the above-
mentioned 4 abdominal acupuncture points. The needles
will be inserted horizontally to a depth of 50–80 mm and
will be connected to the LipoDR electrical stimulator.
Electrical stimulation will consist of biphasic constant
current (2 mA) pulses of 25 Hz for 25 minutes followed
by 60 Hz for 5 minutes.
Sham acupuncture control group
The sham acupuncture group will receive non-penetrating
sham acupuncture as a control for manual acupuncture
plus placebo acupuncture without electrical stimulation as
a control for electroacupuncture at the same time twice a
week for 6 weeks.
Sham acupuncture treatment will be administered
using non-penetrating disposable sterile stainless steel
sham needles (40 mm × 0.25 mm) as described by Park
et al. (AcuPrime Co., Ltd., Exeter, UK) [22] to the same
10 acupuncture points as used for the real acupuncture
group. Except for the usage of a semi-blunted needle,
the technique will be the same as that performed in the
real acupuncture group.
At the same time, placebo acupuncture treatment
without electrical stimulation will be administered
using disposable sterile stainless steel needles (90 mm ×
0.25 mm; Dong-bang Acupuncture Inc.) and a LipoDR
dummy device to the 4 predefined non-traditional
abdominal acupuncture points: 2 cm lateral to Tianshu
(ST25) and 2 cm lateral to Shuidao (ST28), bilaterally.
The needles will be inserted horizontally to a depth of
50–80 mm and connected to the LipoDR dummy
device, which is designed to have no electrical stimula-
tion through insulation of electrodes and is left in place
for 30 minutes.
Practitioner background
The real and sham acupuncture treatments will be
conducted by KMDs licensed by the Korean Ministry of
Health and Welfare who specialize in Korean rehabilita-
tion medicine with at least 4 years of clinical experience.
They will be required to take an educational course to
strictly adhere to the study protocol and be familiar with
administering the study treatments. All practitioners will
undergo intensive and customized training for a full
understanding of the “sham acupuncture” procedure and
will be trained to administer real acupuncture using a
sham needle device. The techniques for all the treatment
procedures will be standardized among practitioners.Outcome
Primary outcome measurement
The primary outcome measure is the serum cholesterol
levels including HDL cholesterol, LDL cholesterol, and
triglyceride (TG) levels. Peripheral blood will be drawn
from the antecubital veins of the subjects in the real and
sham acupuncture groups at baseline (visit 2) and end-
point (visit 14: within 3 days after completion of the 6-
week treatment) after a 10–12 hour overnight fast. Blood
samples will be collected in serum-separating tubes (5
mL), sodium fluoride tubes (3 mL), and EDTA-coated
tubes (2 mL) and will be centrifuged at 3,000 rpm for 10
minutes to separate either serum or plasma depending
on the requirement of the analysis. Aliquots of plasma
and sera will be obtained, and serum-separating tubes
and sodium fluoride tubes will be stored at 2 to 10 °C
while EDTA-coated tubes will be stored at −80 °C for
further analysis. Analysis of TG, HDL cholesterol, LDL
cholesterol, free fatty acids, glucose, hs-CRP, and insulin
will be performed by an outsourcing laboratory (EOne
Laboratories, Incheon, South Korea), and analysis of other
lipids, amino acids, and carnitines will be commissioned
to the research laboratory of the College of Pharmacy,
Hanyang University in Korea.
Secondary outcome measurements
Body weight, body fat mass, and muscle mass will be
measured by bioelectrical impedance analysis using a
body composition analyzer (InBody 720, InBody Co.,
Ltd., Seoul, Korea) and waist and hip circumference will
be measured three times by the same observer according
to the World Health Organization (WHO) method [23],
midpoint between the lower end of the rib cage and top
of the iliac crest in a standing position, which is usually
3 cm above the anterior superior iliac spine and the
widest portion of the buttocks at baseline, at 2, 3, 4, 5,
and 6 weeks and endpoint (visits 2, 4, 6, 8, 10, 12, 14).
Serum metabolic profile including the following will
be determined: phospholipids, fatty acids, valine, tyro-
sine, leucine, glycine, alanine, glutamic acid, histidine,
pipecolic acid, L-carnitine, acetylcarnitine, propionylcarni-
tine, butyrylcarnitine, isovalerylcarnitine, hexanoylcarnitine,
ocatanoylcarnitine, decanoylcarnitine, dodecanoylcarnitine,
tetradeconoylcarnitine, hexadecanoylcarnitine, and octade-
canoylcarnitine. Glucose, hs-CRP, and insulin will also be
measured (visits 2, 14).
The International Physical Activity Questionnaire
(IPAQ) [24] will be used to estimate physical activities
at baseline and endpoint (visits 2, 14). IPAQ is a seven-
item instrument consisting of six questions that partici-
pants answer to record the number of days (frequency)
and the number of minutes per day (duration) of their
participation in all types of vigorous or moderate physical
activities including walking during the last 7 days. In
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participants spend sitting during an average weekday.
IPAQ is considered a reasonably valid measurement tool
for measuring habitual physical activities based on a re-
cent meta-analysis [25].
The Social Readjustment Rating Scale (SRRS) [26] and
the Stress Response Inventory (SRI) [27] will be used to
assess stress response at baseline and endpoint (visits 2,
14). SRRS is a very well-known 43 life events-list scale
measuring stress that affects health based on a relative
score. Subsequent validation has supported the links
between stress and illness [28]; however, the scale has
been criticized for its limited clinical utility. SRI includes
emotional, somatic, cognitive, and behavioral stress re-
sponses and has a significantly high reliability and valid-
ity in clinical practice [27].
The Fatigue Severity Scale (FSS) [29] will be used to
assess fatigability at baseline, 2, 3, 4, 5, and 6 weeks, and
endpoint (visits 2, 4, 6, 8, 10, 12, 14). FSS is the most
commonly used 9-item self-report questionnaire to
measure fatigue [30] and was validated as a simple and
reliable instrument to assess and quantify fatigue for
clinical and research purposes [31].
The Korean version of Beck’s Depression Inventory
(BDI) [32] will be used to measure depressive symptoms
at baseline and endpoint (visits 2, 14). BDI is a 21-item
self-administered questionnaire with each item having aTable 1 Schedule for data collection, treatments, and outcome mea
Period S T
Visit 1 2 3 4 5















Adverse events ○ ○ ○ ○
Credibility test
S screening period, T treatment period, F follow-up period, BIA bioelectrical impeda
Physical Activity Questionnaire, SRRS Social Readjustment Rating Scale, SRI Stress Re
a Baseline (immediately before the first treatment); b end of 6-week treatment; c en0–3 response format and a maximum theoretical score of
63. The psychometric quality of this test is very good [33].
Urine samples will be measured at baseline and end-
point (visits 2, 14). Liquid chromatography quadrupole
time-of-flight mass spectrometry-based nontargeted
metabolomic analysis will be conducted with urine and
serum samples.
Other assessment measures
The validated Korean version of the credibility test, which
was first proposed by Vincent [21], will be used to assess
the credibility of real and sham acupuncture treatments at
endpoint (visit 14).
An overview of the outcome measurement time points
is presented in Table 1.
Sample size
The following hypotheses are related to the differences
between the treatment and control groups:
H0 : μc ¼ μt
H1 : μc ≠ μt
where μt is the mean TG level in the real acupuncture
treatment group and μc is the mean TG level in the
sham acupuncture control group at endpoint.surements
F
6 7 8 9 10 11 12 13 14
3 3 4 4 5 5 6 6b 7c
○ ○ ○ ○ ○ ○ ○ ○
○
○ ○ ○ ○ ○




○ ○ ○ ○ ○
○
○
○ ○ ○ ○ ○ ○ ○ ○ ○
○
nce analysis, WC waist circumference, HC hip circumference, IPAQ International
sponse Inventory, FSS Fatigue Severity Scale, BDI Beck’s Depression Inventory
dpoint (within 3 days after completion of the 6-week treatment)
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expect the mean difference will be 32.5 with a standard
deviation of 56.907 between the two groups.
For the mean comparison method of the two-sample
t-test model, this study will use a level of significance of
α = 0.05 and a power of 1-β = 0.80 and the following
two-sided test:
N ¼ 2 Zα þ Zβ
 2  σ2
δ2




For equal allocation of the two groups, the total sam-
ple size required when considering a dropout rate of 20
% is 120 subjects with 60 subjects in each group.
Statistical analysis
All analyses will be performed using SPSS for Windows
(version 18.0; IBM Corp., Armonk, NY, USA) and a
significance level set at 0.05 by a statistician blinded to
the allocation of groups. Statistical analysis will be
conducted using the principles of the intention-to-treat
(ITT) [34] and the per-protocol (PP) [35] analyses. We
will apply the last observation carried forward (LOCF)
analysis for ITT analysis.
The two-sample t-test for quantitative data and the
chi-square test for qualitative data will be performed to
test homogeneity of the baseline characteristics between
the two groups. Analysis of covariance (ANCOVA) will be
used for adjustment of baseline characteristics if there is a
possibility of covariance. The two-sample t-test will be
used to compare the primary and secondary variables of
the two groups between baseline and endpoint. Repeated
measure analysis of variance (ANOVA) will be performed
for the different time point assessments between groups
and interaction between groups and observed time. A
mixed model approach will also be used if necessary.
Adverse events
Any expected or unexpected adverse events will be
recorded and described as frequency and percentage by
the participants and practitioners at every visit to
completion. The adverse events known related to acu-
puncture treatment include local bleeding or pain at the
acupuncture points, local redness or bruising, itching,
and dizziness during treatment [36]. If any serious
adverse event occurs, detailed events including the date
of occurrence, measures taken related to the treatment,
causal relationship with the treatment, and treatment of
the adverse event will be announced to the principal
investigator and the institutional review board (IRB)
immediately, and direct actions will be supplied to those
involved.Ethics
The research protocol was reviewed and approved by
the IRB of the Korean Medicine Hospital of Kyung Hee
University at Gangdong [KHNMCOH 2013-01-020].
Written informed consent will be obtained from all
participants prior to enrollment in the study.
Discussion
So far, one clinical trial has examined the effect of
acupuncture on metabolic parameters in obese patients
[18], which used serum cholesterol and TG levels. Re-
ferring to the previous study, we will use serum choles-
terol levels including LDL, HDL, and TG levels among
serum metabolic parameters as the primary outcome
measurement. We will also determine other serum meta-
bolic profiles as secondary outcome measurements, be-
cause the main purpose of this study is to assess the
efficacy of acupuncture on obesity from the perspective of
metabolomics and therefore better understand the patho-
physiological mechanism of obesity and acupuncture.
Metabolomics is defined as a technology that aims to
profile metabolite changes in response to a genetic alter-
ation or to pathophysiological stimuli [37, 38], and it
provides invaluable tools for molecular biology approaches
[39]. When applied to obesity, a number of metabolic
perturbations, including imbalance of glucose metabolism
and dyslipidemia in key organs and blood plasma, result
when one consumes a high-fat diet [7]. Thus, metabolic
changes are central to obesity, and we expect that any
process aimed at measuring global metabolism changes
would provide good evidence for the effect of acupuncture
on obesity.
We adopted a complex intervention of manual acu-
puncture plus electroacupuncture treatment for the real
acupuncture treatment group because it is the most
common approach used by KMDs in South Korea
today. A review of studies on acupuncture for obesity
reported that manual acupuncture and electroacupunc-
ture are more often applied in clinical trials than
auricular acupuncture and moxibustion therapy [40]. In
particular, electroacupuncture was reported to decrease
the serum TG, total cholesterol, and LDL cholesterol
[18] and was effective on abdominal obesity [41]; thus,
we decided to apply electroacupuncture on abdominal
acupuncture points.
We chose non-penetrating sham acupuncture plus
placebo acupuncture (non-acupuncture points) without
electrical stimulation for control. In a previous study, ap-
plying sham acupuncture as a control allowed complete
subject blinding [22]. Thus, sham acupuncture is consid-
ered to be a proper control for manual acupuncture.
Additionally, instead of electroacupuncture on abdom-
inal acupuncture points, we decided to use placebo acu-
puncture on abdominal non-acupuncture points without
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dummy device was designed to have no electrical stimu-
lation by insulation of the electrodes. The intensity of
electrical stimulation from both real and dummy devices
will be maintained under a certain level so that subjects
in either group cannot perceive the electric current.
Patients will be informed about the two types of acu-
puncture in the study as follows: “In this study, different
types of acupuncture will be compared. The electric
current will flow but with intensity under a fixed level
which you cannot detect.”
In conclusion, this randomized, patient-assessor blind,
sham-controlled clinical trial will provide important clin-
ical evidence for the efficacy of acupuncture for obesity by
using metabolomics methods, and will contribute to our
understanding of the pathophysiological mechanisms of
obesity as they relate to acupuncture.
Trial status
The participants are currently being recruited for the
present study.
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